TELA Bio Announces Q2 2026 Earnings Call and Leadership Transition
TELA Bio (NASDAQ: TELA) held its second-quarter earnings call for fiscal year 2026 on August 10, 2026. During the call, the company announced a leadership transition with Heather Getz appointed as Chief Executive Officer and director, succeeding Antony Koblish who founded the firm. The board praised Koblish's contributions to TELA Bio’s growth and innovation in soft tissue reconstruction products like OviTex. Getz expressed enthusiasm about joining during an exciting phase for the company, highlighting its differentiated product portfolio focused on hernia repair and plastic surgery with strong clinical support. The call included standard forward-looking statements regarding future performance and risks outlined by regulatory filings.
Tickers: $TELA